1Sartor RB. Therapeutic manipulation of the enteric microfloraininflammatory bowel diseases: antibiotics, probiotics, and prebiotics.Gastroenterology, 2004; 126:1620 - 1633.
2Dotan I, Rachmilewitz D. Probiotics in inflammatory bowel disease:possible mechanisms of action. Current Opinion in Gastroenterology,2005; 21:426- 430
3Schultz M, Scholmerich J,Rath HC.Rationale forprobiotic and antibiotic treatment strategies in inflammatory bowel dieases. Dig Dis ,2003; 21:105 - 128
4Mimura T, Rizzello F, Helwig U , al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut, 2004; 53:108 - 114
5Gosselink MP, Schouten WR, van Lieshout LM. Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum, 2004; 47:876- 884
6Kruis W, Fric P, Pokrotnieks J, et al . Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut, 2004; 53:1617 - 1623
7Kruis W, Schutz E, Fric P, et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis, AlimentPharmacolTher, 1997; 11:853-858
8Kato K, Mizuno S, Umesaki Y, et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol ther, 2004; 20:1133 - 1141
9Tursi A, Brandimarte G, Giorgetti GM, et al. low-dose balsalazide plus a highpotency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-tomoderate ulcerative colitis. Med Sci Monit, 2004; 10:p1126 - p1131
10Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenteroll Hepatol, 2003;15:697 - 698
